AR085273A1 - Formulacion liquida libre de propelente que comprende una droga antimuscarinica - Google Patents
Formulacion liquida libre de propelente que comprende una droga antimuscarinicaInfo
- Publication number
- AR085273A1 AR085273A1 ARP120100539A ARP120100539A AR085273A1 AR 085273 A1 AR085273 A1 AR 085273A1 AR P120100539 A ARP120100539 A AR P120100539A AR P120100539 A ARP120100539 A AR P120100539A AR 085273 A1 AR085273 A1 AR 085273A1
- Authority
- AR
- Argentina
- Prior art keywords
- formulation according
- group
- formulation
- compound
- cosolvent
- Prior art date
Links
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- 239000012669 liquid formulation Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 7
- 239000000203 mixture Substances 0.000 abstract 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000006184 cosolvent Substances 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 238000002663 nebulization Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 2
- 239000003380 propellant Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000006199 nebulizer Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulación farmacéutica líquida, libre de propelente para administración mediante nebulización que comprende una droga antimuscarínica como ingrediente activo. Proceso para preparar la formulación y su uso en la prevención y/o el tratamiento de un amplio rango de condiciones incluyendo trastornos respiratorios.Reivindicación 1: Una formulación farmacéutica líquida libre de propelente para administración a través de nebulización, caracterizada porque comprende un compuesto de fórmula general (1) en donde: R1 es un grupo de la fórmula: ---(CH2)p---P---W en donde p es 0 o un número entero entre 1 y 4; P está ausente o se selecciona del grupo que consiste en O, S, SO, SO2 y CO; W se selecciona del grupo que consiste en H, arilo y heteroarilo, en donde el arilo y el heteroarilo están sustituidos opcionalmente con uno o más sustituyentes que se seleccionan del grupo que consiste en átomos de halógeno, OH, SH, NO2, CN, COOH y NH2; A- representa un anión fisiológicamente aceptable; en donde dicho compuesto se disuelve en un solvente que comprende al menos 75% v/v de agua y un cosolvente opcional miscible con agua; y en donde el pH de la solución que se formó está comprendido entre 3,0 y 5,5. Reivindicación 3: La formulación de acuerdo a la reivindicación 1 ó 2, caracterizada porque el compuesto de fórmula general (1) está presente en una concentración que está comprendida entre 0,001 y 7 mg/ml. Reivindicación 7: La formulación de acuerdo a cualquiera de las reivindicaciones precedentes, caracterizada porque el pH se ajusta mediante el uso de un agente amortiguador que comprende ácido cítrico. Reivindicación 8: La formulación de acuerdo a cualquiera de las reivindicaciones 1 a 7, caracterizada porque el cosolvente opcional es etanol. Reivindicación 9: La formulación de acuerdo a cualquiera de las reivindicaciones 1 a 7, caracterizada porque el cosolvente opcional es glicerol o propilenglicol. Reivindicación 11: La formulación de acuerdo a la reivindicación 10, caracterizada porque dicho agente terapéutico adicional se elige del grupo que consiste en agonistas b2, corticoesteroides, o inhibidores de fosfodiesterasa-4 (PDE4). Reivindicación 15: Un conjunto de componentes caracterizado porque comprende: (a) una formulación de acuerdo a cualquiera de las reivindicaciones 1 a 11 rellena dentro de un vial; y (b) un nebulizador.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11154862 | 2011-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR085273A1 true AR085273A1 (es) | 2013-09-18 |
Family
ID=44168126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120100539A AR085273A1 (es) | 2011-02-17 | 2012-02-16 | Formulacion liquida libre de propelente que comprende una droga antimuscarinica |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120220557A1 (es) |
| EP (1) | EP2675452A1 (es) |
| KR (1) | KR20140003504A (es) |
| CN (1) | CN103347518A (es) |
| AR (1) | AR085273A1 (es) |
| BR (1) | BR112013019876A2 (es) |
| CA (1) | CA2827299A1 (es) |
| RU (1) | RU2013138140A (es) |
| WO (1) | WO2012110462A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2154136A1 (en) | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| KR20130111968A (ko) * | 2010-06-22 | 2013-10-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 알칼로이드 아미노에스테르 유도체 및 이의 의약 조성물 |
| CN111840256A (zh) * | 2019-04-29 | 2020-10-30 | 上海谷森医药有限公司 | 一种雾化吸入剂及其制备方法 |
| US20200405700A1 (en) * | 2019-06-27 | 2020-12-31 | Cai Gu Huang | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide |
| FI4188327T3 (fi) | 2020-07-31 | 2025-07-25 | Chemo Res S L | Yhdistelmähoito inhalaatioannosteluun |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158196A1 (en) * | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
| DE10206505A1 (de) * | 2002-02-16 | 2003-08-28 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern |
| DE10056104A1 (de) * | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
| US20020193392A1 (en) * | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
| AU2002228015B2 (en) | 2000-12-22 | 2007-08-23 | Almirall, S.A. | Quinuclidine carbamate derivatives and their use as M3 antagonists |
| EA006505B1 (ru) | 2001-12-20 | 2005-12-29 | Лабораториос С.А.Л.В.А.Т.,С.А. | Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора |
| US7452523B2 (en) * | 2004-01-27 | 2008-11-18 | Gilead Sciences, Inc. | Targeted delivery of lidocaine and other local anesthetics and a method for treatment of cough and tussive attacks |
| EP1882691A1 (en) | 2006-07-26 | 2008-01-30 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine derivatives as M3 antagonists |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
-
2012
- 2012-02-10 US US13/370,380 patent/US20120220557A1/en not_active Abandoned
- 2012-02-13 CN CN2012800077854A patent/CN103347518A/zh active Pending
- 2012-02-13 RU RU2013138140/15A patent/RU2013138140A/ru not_active Application Discontinuation
- 2012-02-13 WO PCT/EP2012/052425 patent/WO2012110462A1/en not_active Ceased
- 2012-02-13 EP EP12706504.3A patent/EP2675452A1/en not_active Withdrawn
- 2012-02-13 BR BR112013019876A patent/BR112013019876A2/pt not_active IP Right Cessation
- 2012-02-13 KR KR1020137019587A patent/KR20140003504A/ko not_active Withdrawn
- 2012-02-13 CA CA2827299A patent/CA2827299A1/en not_active Abandoned
- 2012-02-16 AR ARP120100539A patent/AR085273A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2675452A1 (en) | 2013-12-25 |
| BR112013019876A2 (pt) | 2016-10-11 |
| CA2827299A1 (en) | 2012-08-23 |
| RU2013138140A (ru) | 2015-02-20 |
| CN103347518A (zh) | 2013-10-09 |
| US20120220557A1 (en) | 2012-08-30 |
| WO2012110462A1 (en) | 2012-08-23 |
| KR20140003504A (ko) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR085273A1 (es) | Formulacion liquida libre de propelente que comprende una droga antimuscarinica | |
| AR081967A1 (es) | Formulacion en polvo seca que comprende una droga antimuscarinica | |
| AR082049A1 (es) | Formulaciones liquidas de rupatadina fumarato | |
| EA201492021A1 (ru) | Антительный состав | |
| AR025434A1 (es) | Formulacion farmaceutica con contenido de derivados de benzamida, con solubilidad y absorcion oral mejoradas | |
| WO2012015810A3 (en) | Pharmaceutical compositions containing pemetrexed having extended storage stability | |
| RU2010139958A (ru) | Стабилизированная фармацевтическая композиция, cодержащая доцетаксель | |
| ES2912327T3 (es) | Composición acuosa oftálmica | |
| JP2013519653A5 (es) | ||
| JP2015007136A5 (es) | ||
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| US20170239173A1 (en) | Transdermal absorption enhancer and transdermal absorption enhancement aid | |
| JP2016503058A5 (es) | ||
| JP2017514924A5 (es) | ||
| JP2013518036A (ja) | 過増殖性疾患、自己免疫疾患、および心疾患の治療のための３−キヌクリジノンを含有する水溶液 | |
| WO2009007137A3 (en) | Pharmaceutical composition for topical application of poorly soluble compounds | |
| RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
| WO2011111070A2 (en) | Novel injectable combination | |
| EA023022B1 (ru) | Высококонцентрированная парентеральная композиция парацетамола и способ её получения | |
| FI4000628T3 (fi) | Koostumus ja menetelmä vankomysiinin oraaliselle nesteelle | |
| JP5922609B2 (ja) | ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物 | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| JP6333023B2 (ja) | 水性医薬組成物 | |
| AR038764A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio | |
| ES2883956T3 (es) | Composición oftálmica que comprende ácido lipoico y ácido hialurónico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |